Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06847464 · ClinicalTrials.gov registry record · Phase 1
A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
A Phase 1 study of RSV Infection and Drug-Drug Interaction (DDI), sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT06847464: Completed Phase 1 study of RSV Infection and Drug-Drug Interaction (DDI), sponsored by Enanta Pharmaceuticals.
NCT06847464 is a Phase 1 study of RSV Infection and Drug-Drug Interaction (DDI) that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 48 participants, below the 741-participant average among 8 other RSV Infection trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06847464, a Phase 1 study of RSV Infection and Drug-Drug Interaction (DDI), has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim of the study is to assess the effect of itraconazole, carbamazepine, quinidine, and fluconazole individually on the pharmacokinetics and safety of EDP-323 in healthy adult participants. Each participant's duration in the study will be dependent upon which study part they are enrolled.
Conditions Studied
Interventions
- DRUG Itraconazole
- DRUG carbamazepine
- DRUG EDP-323
Study Locations (1)
Texas
- ICON, plc - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2025-01-27 |
| Est. Completion | 2025-06-01 |
| Phase | Phase 1 |
What the finished NCT06847464 record still lists
NCT06847464 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 741-participant average among 8 other RSV Infection trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with RSV Infection appearing as the primary indexed condition, and to 3 interventions - of which Itraconazole is the first listed.
NCT06847464 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06847464 about?
NCT06847464 is a clinical study titled "A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.". The primary aim of the study is to assess the effect of itraconazole, carbamazepine, quinidine, and fluconazole individually on the pharmacokinetics and safety of EDP-323 in healthy adult participants. Each participant's duration in the study will be dependent upon which study part they are enrolled...
What is the current status of trial NCT06847464?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2025-01-27. Estimated completion is 2025-06-01.
What conditions does trial NCT06847464 study?
This clinical trial studies the following conditions: RSV Infection, Drug-Drug Interaction (DDI).
What interventions are being tested in trial NCT06847464?
The interventions under investigation include: Itraconazole (DRUG), carbamazepine (DRUG), EDP-323 (DRUG).
Who is sponsoring clinical trial NCT06847464?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06847464 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for RSV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06847464's enrollment target sits among peer trials
48 8th of 8 higher than 1 of 8 other RSV Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other RSV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
RECRUITING · Phase 1
-
A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants
COMPLETED · Phase 1
-
A Study of EDP-323 in Healthy Subjects
COMPLETED · Phase 1
-
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
RECRUITING · Phase 3
-
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
RECRUITING
-
SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI